JP2024511881A5 - - Google Patents

Info

Publication number
JP2024511881A5
JP2024511881A5 JP2023560997A JP2023560997A JP2024511881A5 JP 2024511881 A5 JP2024511881 A5 JP 2024511881A5 JP 2023560997 A JP2023560997 A JP 2023560997A JP 2023560997 A JP2023560997 A JP 2023560997A JP 2024511881 A5 JP2024511881 A5 JP 2024511881A5
Authority
JP
Japan
Prior art keywords
dimethyl
cyclopropyl
azabicyclo
carboxamide
hexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511881A (ja
Filing date
Publication date
Priority claimed from GBGB2104742.8A external-priority patent/GB202104742D0/en
Priority claimed from GBGB2107026.3A external-priority patent/GB202107026D0/en
Application filed filed Critical
Priority claimed from PCT/GB2022/050836 external-priority patent/WO2022208113A1/en
Publication of JP2024511881A publication Critical patent/JP2024511881A/ja
Publication of JP2024511881A5 publication Critical patent/JP2024511881A5/ja
Pending legal-status Critical Current

Links

JP2023560997A 2021-04-01 2022-04-01 SARS-COV-2 Mpro阻害剤化合物 Pending JP2024511881A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2104742.8 2021-04-01
GBGB2104742.8A GB202104742D0 (en) 2021-04-01 2021-04-01 Sars-Cov-2 MPRO inhibitor compounds
GB2107026.3 2021-05-17
GBGB2107026.3A GB202107026D0 (en) 2021-05-17 2021-05-17 SARS-COV-2 MPRO inhibitor compounds
PCT/GB2022/050836 WO2022208113A1 (en) 2021-04-01 2022-04-01 Sars-cov-2 mpro inhibitor compounds

Publications (2)

Publication Number Publication Date
JP2024511881A JP2024511881A (ja) 2024-03-15
JP2024511881A5 true JP2024511881A5 (cg-RX-API-DMAC7.html) 2025-04-09

Family

ID=81307814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560997A Pending JP2024511881A (ja) 2021-04-01 2022-04-01 SARS-COV-2 Mpro阻害剤化合物

Country Status (7)

Country Link
US (1) US20240217930A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313305A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024511881A (cg-RX-API-DMAC7.html)
KR (1) KR20240004275A (cg-RX-API-DMAC7.html)
AU (1) AU2022247287A1 (cg-RX-API-DMAC7.html)
CA (1) CA3213008A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022208113A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
GB202214644D0 (en) * 2022-10-05 2022-11-16 Heptares Therapeutics Ltd Sars-cov-2 mpro inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
CA3180177A1 (en) * 2020-05-08 2021-11-11 The Board Of Trustees Of The Leland Stanford Junior University Protease inhibitors for treatment or prevention of coronavirus disease

Similar Documents

Publication Publication Date Title
RU2494095C2 (ru) Модифицированные миметики лизина
CN105283177B (zh) 用作组蛋白脱甲基酶kdm1a的抑制剂的环丙胺衍生物
JP2023529354A5 (cg-RX-API-DMAC7.html)
RU2471781C2 (ru) Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии
TW202327569A (zh) 包含tead抑制劑的藥物組合及其用於癌症治療之用途
CN105121430B (zh) 用于治疗自身免疫性和炎性疾病的类维生素A相关的孤儿受体γ(RORγ)的调节剂
CN104395288B (zh) 用于治疗尤文肉瘤家族肿瘤的方法和组合物
RU2018127315A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний
SI9420017A (en) Hiv protease inhibitors in pharmaceutical combinations for the treatment of aids
JP2018507877A5 (cg-RX-API-DMAC7.html)
EA001221B1 (ru) Тгф-содержащие сульфонамидные ингибиторы аспартил-протеазы
JP6217866B2 (ja) Kcnq2〜5チャネル活性化剤
JP2007538024A5 (cg-RX-API-DMAC7.html)
JP2021513972A (ja) 社会的機能障害の治療方法
JP2024545135A5 (cg-RX-API-DMAC7.html)
CN1082543A (zh) 吲哚衍生物
JP2012509940A5 (cg-RX-API-DMAC7.html)
JP2024508045A5 (cg-RX-API-DMAC7.html)
JP2023545046A5 (cg-RX-API-DMAC7.html)
JPWO2009136625A1 (ja) 環状アミン−1−カルボン酸エステル誘導体およびそれを含有する医薬組成物
JP2019516707A5 (cg-RX-API-DMAC7.html)
JP2023547241A5 (cg-RX-API-DMAC7.html)
JP2016512232A (ja) 運動障害の予防又は治療用フェニルカルバメート化合物
JP2023525359A5 (cg-RX-API-DMAC7.html)
IL293703A (en) Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms